US Drug Prices: A Mixed Reality

The TrumpRx site launched in January promised cheaper medicines for Americans, but a recent check shows that about one third of the 54 drugs listed are actually cheaper in Britain. The UK, which also struck a deal to keep U. S. drug tariffs out of the way, pays 67 % to 82 % less for drugs like Pfizer’s arthritis pill Xeljanz, AstraZeneca’s diabetes medicine Farxiga and GSK’s lung inhalers. President Trump has bragged that the website proves he can cut U. S. drug costs “from the highest to the lowest, ” even claiming some medicines are now 300 % to 600 % cheaper. Those numbers don’t line up with the actual prices, and critics point out that TrumpRx shows only a rough ceiling on what cash‑paying patients might spend. Most Americans use insurance, so the real out‑of‑pocket costs are different.The most dramatic savings appear for weight‑loss injections. Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy were reduced to about $149–$350 a month, down from over $1, 000. Fertility drugs also saw big cuts, with EMD Serono reporting an 84 % discount on its U. S. fertility drugs. Still, the U. K. NHS sets prices through cost‑control deals and a flat prescription charge of £9. 90 in England, while prescriptions are free elsewhere. Drugmakers have mixed reactions. Swiss firms Novartis and Roche say the deals won’t hurt them, whereas Novo Nordisk warns sales could drop 13 % next year. Johnson & Johnson estimates a hit of hundreds of millions, but analysts note that its massive sales volume means the impact is relatively small. The key factor is how much a company sells through government programs versus private sales. Experts say the voluntary nature of the deals means there is no real enforcement, so they may not solve the broader problem of high drug prices. The U. K. ’s approach relies on negotiating lower prices directly with manufacturers, a strategy that seems to yield better results for many patients.